JP5855568B2 - 癌の治療法 - Google Patents

癌の治療法 Download PDF

Info

Publication number
JP5855568B2
JP5855568B2 JP2012529881A JP2012529881A JP5855568B2 JP 5855568 B2 JP5855568 B2 JP 5855568B2 JP 2012529881 A JP2012529881 A JP 2012529881A JP 2012529881 A JP2012529881 A JP 2012529881A JP 5855568 B2 JP5855568 B2 JP 5855568B2
Authority
JP
Japan
Prior art keywords
composition
cdp
cancer
conjugate
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012529881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504630A5 (cg-RX-API-DMAC7.html
JP2013504630A (ja
Inventor
ユン イェン，
ユン イェン，
トーマス シュレップ，
トーマス シュレップ，
ジョン ライアン，
ジョン ライアン，
マーク デイビス，
マーク デイビス，
ジェイムス シー． オリバー，
ジェイムス シー． オリバー，
Original Assignee
セルリアン・ファーマ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルリアン・ファーマ・インコーポレイテッド filed Critical セルリアン・ファーマ・インコーポレイテッド
Publication of JP2013504630A publication Critical patent/JP2013504630A/ja
Publication of JP2013504630A5 publication Critical patent/JP2013504630A5/ja
Application granted granted Critical
Publication of JP5855568B2 publication Critical patent/JP5855568B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012529881A 2009-09-15 2010-09-15 癌の治療法 Expired - Fee Related JP5855568B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24275209P 2009-09-15 2009-09-15
US61/242,752 2009-09-15
US31703910P 2010-03-24 2010-03-24
US61/317,039 2010-03-24
US33215010P 2010-05-06 2010-05-06
US61/332,150 2010-05-06
US38185110P 2010-09-10 2010-09-10
US61/381,851 2010-09-10
PCT/US2010/048973 WO2011034954A1 (en) 2009-09-15 2010-09-15 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014223985A Division JP2015025020A (ja) 2009-09-15 2014-11-04 癌の治療法

Publications (3)

Publication Number Publication Date
JP2013504630A JP2013504630A (ja) 2013-02-07
JP2013504630A5 JP2013504630A5 (cg-RX-API-DMAC7.html) 2013-10-17
JP5855568B2 true JP5855568B2 (ja) 2016-02-09

Family

ID=43758997

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012529881A Expired - Fee Related JP5855568B2 (ja) 2009-09-15 2010-09-15 癌の治療法
JP2014223985A Withdrawn JP2015025020A (ja) 2009-09-15 2014-11-04 癌の治療法
JP2016045695A Pending JP2016106143A (ja) 2009-09-15 2016-03-09 癌の治療法
JP2017196769A Withdrawn JP2017226708A (ja) 2009-09-15 2017-10-10 癌の治療法
JP2020109574A Pending JP2020164547A (ja) 2009-09-15 2020-06-25 癌の治療法
JP2022135758A Withdrawn JP2022166327A (ja) 2009-09-15 2022-08-29 癌の治療法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014223985A Withdrawn JP2015025020A (ja) 2009-09-15 2014-11-04 癌の治療法
JP2016045695A Pending JP2016106143A (ja) 2009-09-15 2016-03-09 癌の治療法
JP2017196769A Withdrawn JP2017226708A (ja) 2009-09-15 2017-10-10 癌の治療法
JP2020109574A Pending JP2020164547A (ja) 2009-09-15 2020-06-25 癌の治療法
JP2022135758A Withdrawn JP2022166327A (ja) 2009-09-15 2022-08-29 癌の治療法

Country Status (11)

Country Link
US (5) US20110160159A1 (cg-RX-API-DMAC7.html)
EP (1) EP2477985B1 (cg-RX-API-DMAC7.html)
JP (6) JP5855568B2 (cg-RX-API-DMAC7.html)
CN (1) CN102666533A (cg-RX-API-DMAC7.html)
AU (1) AU2010295646B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012005594A2 (cg-RX-API-DMAC7.html)
CA (2) CA2774015A1 (cg-RX-API-DMAC7.html)
EA (1) EA201200486A1 (cg-RX-API-DMAC7.html)
IL (1) IL218575A0 (cg-RX-API-DMAC7.html)
MX (2) MX342709B (cg-RX-API-DMAC7.html)
WO (1) WO2011034954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
WO2011051894A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
EP2809686A4 (en) * 2012-01-31 2015-11-25 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014055913A1 (en) * 2012-10-05 2014-04-10 Cerulean Pharma Inc. Treatment of cancer
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN104837508A (zh) 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2014128108A1 (de) 2013-02-21 2014-08-28 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1 c3)
EP2801370A1 (en) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3049078B1 (en) * 2013-09-27 2018-06-27 BlueLink Pharmaceuticals, Inc. Treatment of cancer
BR112016016932A8 (pt) * 2014-01-24 2020-06-16 Sirtex Medical Ltd uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu)
NZ734256A (en) * 2015-02-12 2019-02-22 Beyondspring Pharmaceuticals Inc Use of plinabulin in combination with immune checkpoint inhibitors
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN108026075B (zh) 2015-07-13 2021-06-29 大连万春布林医药有限公司 普那布林组合物
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
FR3040860B1 (fr) * 2015-09-10 2020-05-15 Universite de Bordeaux Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
US20190133963A1 (en) * 2015-11-03 2019-05-09 Nanoproteagen Polymeric nanoparticles
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
CN109310385A (zh) 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
WO2018102769A1 (en) * 2016-12-01 2018-06-07 Bluelink Pharmaceuticals, Inc. Treatment of cancer
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
BR112020014960A2 (pt) 2018-01-24 2020-12-22 Beyondspring Pharmaceuticals, Inc. Composição e método para redução de trombocitopenia
WO2019232257A1 (en) * 2018-06-01 2019-12-05 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
CN113164600A (zh) 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
US20220072087A1 (en) 2019-01-17 2022-03-10 Biolinerx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
WO2021119464A1 (en) * 2019-12-13 2021-06-17 Veri Nano Inc. Compositions and modular nano- and microparticles for the delivery of various agents and use thereof
JP2023511184A (ja) * 2020-01-22 2023-03-16 メドイミューン・リミテッド 化合物及びその複合体
CN117098531A (zh) * 2021-01-08 2023-11-21 斯塔顿治疗公司 用于肠胃外使用的免疫调节酰亚胺化合物的稳定溶液
CN114904013A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 硫酸乙酰肝素-骨化三醇偶联物，包含其的乙酰肝素酶响应性纳米粒，其制备方法及用途
CN115109258A (zh) * 2021-03-19 2022-09-27 江西中医药大学 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ES2058081T3 (es) 1986-09-05 1994-11-01 American Cyanamid Co Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos.
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU756796B2 (en) * 1998-10-16 2003-01-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Combination therapy with VIP antagonist
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
AU2003243561A1 (en) * 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2003299651A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7358262B2 (en) * 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
CN1216057C (zh) * 2003-03-28 2005-08-24 贵州省生物研究所 喜树碱类似物的衍生物及其制备方法
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
CA2569520C (en) * 2004-06-04 2023-03-14 Genentech, Inc. Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
EP1913157B2 (en) * 2005-06-28 2016-10-26 Genentech, Inc. Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
WO2008148080A2 (en) * 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer

Also Published As

Publication number Publication date
CA2774015A1 (en) 2011-03-24
US20180071404A1 (en) 2018-03-15
JP2017226708A (ja) 2017-12-28
BR112012005594A2 (pt) 2015-09-08
MX2012003046A (es) 2012-09-07
CN102666533A (zh) 2012-09-12
CA2939165A1 (en) 2011-03-24
MX342709B (es) 2016-10-10
JP2022166327A (ja) 2022-11-01
US20110160159A1 (en) 2011-06-30
US20160058875A1 (en) 2016-03-03
IL218575A0 (en) 2012-05-31
JP2020164547A (ja) 2020-10-08
MX366955B (es) 2019-07-31
US20130338103A1 (en) 2013-12-19
WO2011034954A1 (en) 2011-03-24
JP2013504630A (ja) 2013-02-07
JP2015025020A (ja) 2015-02-05
US20130164282A1 (en) 2013-06-27
JP2016106143A (ja) 2016-06-16
AU2010295646B2 (en) 2016-02-11
EP2477985A4 (en) 2013-05-15
EA201200486A1 (ru) 2012-08-30
AU2010295646A1 (en) 2012-04-05
EP2477985A1 (en) 2012-07-25
EP2477985B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
JP5855568B2 (ja) 癌の治療法
US20200375978A1 (en) Treatment of cancer
AU2012229503B2 (en) Treatment of cancer
US20200093932A1 (en) Treatment of cancer
US20110245201A1 (en) Treatment of cancer
EP3049078B1 (en) Treatment of cancer
US20140205594A1 (en) Treatment of cancer
AU2013205079B2 (en) Treatment of cancer
HK1169391A (en) Crlx101 for use in the treatment of cancer
HK1169391B (en) Crlx101 for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150820

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151209

R150 Certificate of patent or registration of utility model

Ref document number: 5855568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees